<DOC>
	<DOCNO>NCT01247493</DOCNO>
	<brief_summary>A phase II clinical trial evaluate efficacy tolerability induction consolidation chemotherapy comprise Fludarabine , cytarabine attenuated-dose Idarubicin ( modified-FLAI ) elderly patient acute myeloid leukemia .</brief_summary>
	<brief_title>Modified-FLAI Induction Consolidation Chemotherapy Elderly Patient With Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>previously untreated AML ( exclude acute promyelocytic leukemia ) age great 60 year old ECOG PS ( Eastern Cooperative Oncology Group Performance scale ) less 2 adequate hepatic/ renal/ cardiac function acute promyelocytic leukemia significant cardiac disease combine nonhematologic malignancy aleukemic leukemia ( granulocytic sarcoma ) CNS ( Central Nervous system ) involvement significant comorbidity/ uncontrollable bleeding tendency</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>fludarabine</keyword>
	<keyword>AML</keyword>
	<keyword>Efficacy</keyword>
	<keyword>tolerability</keyword>
</DOC>